• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腮腺癌颈部的治疗。

Treatment of the neck in carcinoma of the parotid gland.

作者信息

Ali Safina, Palmer Frank L, DiLorenzo Monica, Shah Jatin P, Patel Snehal G, Ganly Ian

机构信息

Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

出版信息

Ann Surg Oncol. 2014 Sep;21(9):3042-8. doi: 10.1245/s10434-014-3681-y. Epub 2014 Apr 10.

DOI:10.1245/s10434-014-3681-y
PMID:24719019
Abstract

PURPOSE

To review our experience in the treatment of the neck in patients with carcinoma of the parotid gland.

METHODS

A total of 263 patients were stratified into 3 groups: no neck dissection (NoND), elective neck dissection (END), and therapeutic neck dissection (TND). Clinicopathological characteristics of END and TND versus NoND were compared by Chi square test. Pathological positivity of each neck level was quantified. Neck recurrence-free survival was determined by Kaplan-Meier statistics.

RESULTS

There were 232 cN0 and 31 cN+ patients. Of the cN0 patients, 74 had END. All cN+ patients had TND. Of the END group, occult neck metastases were detected in 26 (35 %) patients. The percentage of positivity was 6.7, 28.3, 21.3, 10.8, and 6.7 % for levels I to V, respectively. Compared to the NoND group, the END group was more likely to be over 60 years old, to have cT3T4 disease, and to have disease with more aggressive histology. Of the TND group, pathological positivity was found in 87 %. The percentage of positivity was 51.6, 77, 73, 53, and 40 % for levels I to V, respectively. Patients who had disease-positive necks had a poorer neck recurrence-free survival of 84.8 %.

CONCLUSIONS

In patients with cN0 disease, observation of the neck is safe in those who are under 60 years of age with clinical T1 or T2 tumors and who have low-grade histology. END should be carried out in patients with cT3T4 disease or high-grade histology and should involve levels II to IV at a minimum. Patients with cN+ disease commonly have all neck levels involved and therefore should be managed with comprehensive neck dissection.

摘要

目的

回顾我们在腮腺癌患者颈部治疗方面的经验。

方法

总共263例患者被分为3组:未行颈部清扫术(NoND)、选择性颈部清扫术(END)和治疗性颈部清扫术(TND)。通过卡方检验比较END和TND与NoND的临床病理特征。对每个颈部水平的病理阳性情况进行量化。采用Kaplan-Meier统计方法确定颈部无复发生存率。

结果

有232例cN0患者和31例cN+患者。在cN0患者中,74例行END。所有cN+患者均行TND。在END组中,26例(35%)患者检测到隐匿性颈部转移。I至V级的阳性率分别为6.7%、28.3%、21.3%、10.8%和6.7%。与NoND组相比,END组患者更可能年龄超过60岁、患有cT3T4期疾病且组织学表现更具侵袭性。在TND组中,87%发现病理阳性。I至V级的阳性率分别为51.6%、77%、73%、53%和40%。颈部有疾病阳性的患者颈部无复发生存率较差,为84.8%。

结论

对于cN0期疾病患者,年龄小于60岁、临床T1或T2肿瘤且组织学分级低的患者观察颈部是安全的。cT3T4期疾病或组织学分级高的患者应行END,且至少应包括II至IV级。cN+期疾病患者通常所有颈部水平均受累,因此应行根治性颈部清扫术。

相似文献

1
Treatment of the neck in carcinoma of the parotid gland.腮腺癌颈部的治疗。
Ann Surg Oncol. 2014 Sep;21(9):3042-8. doi: 10.1245/s10434-014-3681-y. Epub 2014 Apr 10.
2
Patterns of lymph node metastasis and the management of neck dissection for parotid carcinomas: a single-institute experience.腮腺癌的淋巴结转移模式和颈淋巴结清扫术的处理:单中心经验。
Int J Clin Oncol. 2019 Jun;24(6):624-631. doi: 10.1007/s10147-019-01411-3. Epub 2019 Feb 9.
3
Is level V neck dissection necessary in primary parotid cancer?原发性腮腺癌是否需要进行Ⅴ级颈清扫术?
Laryngoscope. 2015 Jan;125(1):118-21. doi: 10.1002/lary.24772. Epub 2014 Jun 26.
4
Malignant tumours of the parotid gland: management of the neck (including the clinically negative neck) and a literature review.腮腺恶性肿瘤:颈部(包括临床阴性颈部)的处理以及文献回顾。
Br J Oral Maxillofac Surg. 2021 Jul;59(6):665-671. doi: 10.1016/j.bjoms.2020.08.026. Epub 2020 Aug 27.
5
Impact of elective neck dissection vs observation on regional recurrence and survival in cN0-staged patients with squamous cell carcinomas of the upper aerodigestive tract.选择性颈部清扫术与观察对cN0期上消化道鳞状细胞癌患者区域复发及生存的影响
Arch Otolaryngol Head Neck Surg. 2012 Jul;138(7):650-5. doi: 10.1001/archoto.2012.1026.
6
Patterns and treatment of neck metastases in patients with salivary gland cancers.涎腺癌患者颈部转移灶的模式及治疗
J Surg Oncol. 2015 Jun;111(8):1000-6. doi: 10.1002/jso.23914. Epub 2015 May 14.
7
Elective neck dissection versus observation in primary parotid carcinoma.原发性腮腺癌的选择性颈淋巴结清扫术与观察对比
Otolaryngol Head Neck Surg. 2005 Mar;132(3):387-91. doi: 10.1016/j.otohns.2004.09.029.
8
Supraomohyoid neck dissection in the management of oral squamous cell carcinoma: special consideration for skip metastases at level IV or V.舌骨上颈清扫术在口腔鳞状细胞癌治疗中的应用:对IV或V区跳跃性转移的特殊考量
J Oral Maxillofac Surg. 2014 Jun;72(6):1203-11. doi: 10.1016/j.joms.2013.12.008. Epub 2013 Dec 25.
9
Head and neck salivary gland carcinomas--elective neck dissection, yes or no?头颈部唾液腺癌——是否进行选择性颈部清扫术?
J Oral Maxillofac Surg. 2014 Jan;72(1):205-10. doi: 10.1016/j.joms.2013.05.024. Epub 2013 Jul 25.
10
The role of elective neck dissection in high-grade parotid malignancy: A hospital-based cohort study.择期颈清扫术在高级别腮腺恶性肿瘤中的作用:一项基于医院的队列研究。
Laryngoscope. 2020 Jun;130(6):1487-1495. doi: 10.1002/lary.28238. Epub 2019 Aug 29.

引用本文的文献

1
Prognostic Effect of Neck Dissection and Risk Factors for Occult Lymph Node Metastasis in cN0 Parotid Carcinoma.cN0期腮腺癌颈淋巴结清扫术的预后效果及隐匿性淋巴结转移的危险因素
Cancer Innov. 2025 Apr 7;4(3):e70007. doi: 10.1002/cai2.70007. eCollection 2025 Jun.
2
Patterns of lymph node metastasis and treatment outcomes of parotid gland malignancies.腮腺恶性肿瘤的淋巴结转移模式及治疗结果
BMC Oral Health. 2025 Feb 22;25(1):286. doi: 10.1186/s12903-025-05561-x.
3
Recurrence after primary salivary gland carcinoma: Frequency, survival, and risk factors.
原发性唾液腺癌复发:发生率、生存率及危险因素
Head Neck. 2025 Jan;47(1):47-56. doi: 10.1002/hed.27880. Epub 2024 Jul 27.
4
Tumor budding - a potential biomarker in low grade salivary gland carcinomas?肿瘤芽生——低级别涎腺癌的一种潜在生物标志物?
Front Oncol. 2024 Jun 25;14:1410264. doi: 10.3389/fonc.2024.1410264. eCollection 2024.
5
Nomogram based on immune-inflammatory indicators and age-adjusted charlson comorbidity index score to predict prognosis of postoperative parotid gland carcinoma patients.基于免疫炎症指标和年龄调整 Charlson 共病指数评分的列线图预测腮腺癌患者术后预后。
BMC Oral Health. 2024 Jun 22;24(1):718. doi: 10.1186/s12903-024-04490-5.
6
Oncologic outcomes of the most prevalent major salivary gland cancers: retrospective cohort study from single center.最常见的主要涎腺癌的肿瘤学结局:单中心回顾性队列研究。
Eur Arch Otorhinolaryngol. 2024 Aug;281(8):4305-4313. doi: 10.1007/s00405-024-08650-9. Epub 2024 Apr 23.
7
Topography and probability diagram of cervical and intra-parotid lymph node metastasis in parotid gland cancer.腮腺癌颈及腮腺内淋巴结转移的解剖部位和概率图。
Clin Exp Metastasis. 2024 Feb;41(1):33-43. doi: 10.1007/s10585-023-10244-4. Epub 2023 Dec 11.
8
Current management and future challenges in salivary glands cancer.唾液腺癌的当前管理与未来挑战
Front Oncol. 2023 Sep 19;13:1264287. doi: 10.3389/fonc.2023.1264287. eCollection 2023.
9
Do Lymph Node Ratio and Histopathologic Parameters Have Any Prognostic Value in Primary Parotid Gland Carcinomas?淋巴结比率和组织病理学参数在原发性腮腺癌中是否具有任何预后价值?
Turk Arch Otorhinolaryngol. 2023 Jun;61(2):58-65. doi: 10.4274/tao.2023.2023-3-5. Epub 2023 Sep 18.
10
Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up.唾液腺癌:ESMO-欧洲罕见成人实体瘤参考网络(EURACAN)诊断、治疗和随访临床实践指南。
ESMO Open. 2022 Dec;7(6):100602. doi: 10.1016/j.esmoop.2022.100602. Epub 2022 Nov 2.